Advertisement
Advertisement
AUPH
Aurinia Pharmaceuticals Inc
16.46
USDSponsored
+0.25
+1.54%
Nov 06, 15:59 UTC -5
Closed
After-Market
16.46
0.00
0.00%
Aurinia Pharmaceuticals Inc (AUPH) Earnings
AUPH Earnings Reports
Positive Surprise Ratio
AUPH beat 29 of 44 last estimates.
66%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$87.27M
/$0.21
Implied change from Q3 26 (Revenue/ EPS)
+4.27%
/-8.70%
Implied change from Q4 25 (Revenue/ EPS)
+13.17%
/-19.23%
Aurinia Pharmaceuticals Inc earnings per share and revenue
On Oct 30, 2026, AUPH reported earnings of 0.23 USD per share (EPS) for Q3 26, beating the estimate of 0.22 USD, resulting in a 2.50% surprise. Revenue reached 83.70 million, compared to an expected 85.36 million, with a -1.95% difference. The market reacted with a -3.25% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of 0.21 USD, with revenue projected to reach 87.27 million USD, implying an decrease of -8.70% EPS, and increase of 4.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Aurinia Pharmaceuticals Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Aurinia Pharmaceuticals Inc reported EPS of $0.23, beating estimates by 2.5%, and revenue of $83.70M, -1.95% below expectations.
How did the market react to Aurinia Pharmaceuticals Inc's Q3 2026 earnings?
The stock price moved down -3.25%, changed from $17.21 before the earnings release to $16.65 the day after.
When is Aurinia Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Aurinia Pharmaceuticals Inc's next earnings report?
Based on 5
analysts, Aurinia Pharmaceuticals Inc is expected to report EPS of $0.21 and revenue of $87.27M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.